{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:29:49Z","timestamp":1788280189704,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012314","name":"Shinshu University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012314","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>In breast cancer, a low skeletal muscle index (SMI) and prognostic nutritional index (PNI) negatively affect patient outcomes. However, the prognostic implications of changes in these values in patients with metastatic breast cancer (MBC) remain unclear. We evaluated the association between baseline levels and changes in SMI and PNI during eribulin treatment and patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 67 patients with MBC treated with eribulin. SMI and PNI were assessed at baseline (pre-SMI, and pre-PNI) and at disease progression; changes from baseline were calculated. Patient outcomes were compared according to baseline status and direction of change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SMI and PNI were not significantly correlated (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.26, R\u2009=\u20090.02). High pre-SMI and high pre-PNI were associated with significantly improved overall survival (OS) (SMI; hazard ratio [HR]\u2009=\u20090.54,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04, PNI; HR\u2009=\u20090.33,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patients with SMI gain during eribulin had longer OS than those with stable SMI or loss (HR\u2009=\u20090.48,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), whereas PNI increase was not significantly associated with OS (HR\u2009=\u20090.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.32).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline SMI and PNI provide complementary prognostic information in patients with MBC receiving eribulin. Furthermore, on-treatment SMI gain, but not PNI increase, was associated with improved survival. Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-025-07827-y","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:08:01Z","timestamp":1760526481000},"page":"419-429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment"],"prefix":"10.1007","volume":"214","author":[{"given":"Masatsugu","family":"Amitani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-4989","authenticated-orcid":false,"given":"Takaaki","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Kitazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Iji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nami","family":"Kiyosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Katsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Chino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"7827_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older P, the Extended Group for E (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16\u201331","journal-title":"Age Ageing"},{"key":"7827_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367","journal-title":"Eur J Cancer"},{"key":"7827_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jcsm.12267","volume":"9","author":"LE Daly","year":"2018","unstructured":"Daly LE, \u00c9B NB, Power DG, Cushen SJ, James K, Ryan AM (2018) Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle 9:315\u2013325","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7827_CR4","doi-asserted-by":"publisher","first-page":"17683","DOI":"10.1038\/s41598-020-74765-8","volume":"10","author":"SE Park","year":"2020","unstructured":"Park SE, Choi JH, Park JY, Kim BJ, Kim JG, Kim JW, Park JM, Chi KC, Hwang IG (2020) Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer. Sci Rep 10:17683","journal-title":"Sci Rep"},{"key":"7827_CR5","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349","journal-title":"CA Cancer J Clin"},{"key":"7827_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1152\/jappl.2000.89.1.81","volume":"89","author":"I Janssen","year":"2000","unstructured":"Janssen I, Heymsfeld SB, Wang Z, Robert R (2000) Skeletal muscle mass and distribution in 468 men and women aged 18\u201388 yr. J Appl Physiol 89:81\u201388","journal-title":"J Appl Physiol"},{"key":"7827_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12885-020-6645-6","volume":"20","author":"XM Zhang","year":"2020","unstructured":"Zhang XM, Dou QL, Zeng Y, Yang Y, Cheng ASK, Zhang WW (2020) Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review. BMC Cancer 20:172","journal-title":"BMC Cancer"},{"key":"7827_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030596","author":"M Roberto","year":"2024","unstructured":"Roberto M, Barchiesi G, Resuli B, Verrico M, Speranza I, Cristofani L, Pediconi F, Tomao F, Botticelli A, Santini D (2024) Sarcopenia in breast cancer patients: a systematic review and meta-analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16030596","journal-title":"Cancers (Basel)"},{"key":"7827_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.clbc.2024.10.014","volume":"25","author":"A Aktas","year":"2025","unstructured":"Aktas A, Greiner RS, Flores M, Boselli D, Stone T, Wang E, Hadzikadic-Gusic L, Wallander ML, Hecksher A, Bailey-Dorton C, Walsh D (2025) Association of skeletal muscle mass and muscle quality at diagnosis with survival in young women with breast cancer: retrospective observational study. Clin Breast Cancer 25:223\u2013232","journal-title":"Clin Breast Cancer"},{"key":"7827_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12885-022-09443-1","volume":"22","author":"M Amitani","year":"2022","unstructured":"Amitani M, Oba T, Kiyosawa N, Morikawa H, Chino T, Soma A, Shimizu T, Ohno K, Ono M, Ito T, Kanai T, Maeno K, Ito KI (2022) Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer. BMC Cancer 22:327","journal-title":"BMC Cancer"},{"key":"7827_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170634","volume":"12","author":"S Kashiwagi","year":"2017","unstructured":"Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Noda S, Takashima T, Onoda N, Tomita S, Ohsawa M, Hirakawa K, Ohira M (2017) Use of tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer. PLoS ONE 12:e0170634","journal-title":"PLoS ONE"},{"key":"7827_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","volume":"27","author":"Y Miyoshi","year":"2020","unstructured":"Miyoshi Y, Yoshimura Y, Saito K, Muramoto K, Sugawara M, Alexis K, Nomoto K, Nakamura S, Saeki T, Watanabe J, Perez-Garcia JM, Cortes J (2020) High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study. Breast Cancer 27:706\u2013715","journal-title":"Breast Cancer"},{"key":"7827_CR13","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ21-0237","author":"T Oba","year":"2021","unstructured":"Oba T, Maeno K, Amitani M, Shimizu T, Ohno K, Ono M, Ito T, Kanai T, Uehara T, Ito KI (2021) Prognostic significance of neutrophil-to-lymphocyte ratio for long-term outcomes in patients with poorly differentiated thyroid cancer. Endocr J. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0237","journal-title":"Endocr J"},{"key":"7827_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.21873\/anticanres.14794","volume":"41","author":"T Oba","year":"2021","unstructured":"Oba T, Maeno K, Ono M, Ito T, Kanai T, Ito KI (2021) Prognostic nutritional index is superior to neutrophil-to-lymphocyte ratio as a prognostic marker in metastatic breast cancer patients treated with Eribulin. Anticancer Res 41:445\u2013452","journal-title":"Anticancer Res"},{"key":"7827_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12885-020-6647-4","volume":"20","author":"T Oba","year":"2020","unstructured":"Oba T, Maeno K, Takekoshi D, Ono M, Ito T, Kanai T, Ito KI (2020) Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer. BMC Cancer 20:160","journal-title":"BMC Cancer"},{"key":"7827_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07700-9","author":"J-Y Kim","year":"2020","unstructured":"Kim J-Y, Jung EJ, Kim J-M, Lee HS, Kwag S-J, Park J-H, Park T, Jeong S-H, Jeong C-Y, Ju Y-T (2020) Dynamic changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predicts breast cancer prognosis. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-020-07700-9","journal-title":"BMC Cancer"},{"key":"7827_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.radonc.2020.09.012","volume":"154","author":"CH Lin","year":"2021","unstructured":"Lin CH, Chou WC, Wu YY, Lin CY, Chang KP, Liao CT, Ho TY, Yeh CM, Liu CJ, Hung SP, Lee CH, Chen PJ, Chou YC, Fan KH, Huang BS, Tung-Chieh Chang J, Wang CC, Tsang NM (2021) Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: results from a large cohort study. Radiother Oncol 154:76\u201386","journal-title":"Radiother Oncol"},{"key":"7827_CR18","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85:1001\u20131005","journal-title":"Nihon Geka Gakkai Zasshi"},{"key":"7827_CR19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1200\/JCO.2015.63.6043","volume":"34","author":"S Blauwhoff-Buskermolen","year":"2016","unstructured":"Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, Verheul HM (2016) Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 34:1339\u20131344","journal-title":"J Clin Oncol"},{"key":"7827_CR20","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019 Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C, Investigators E (2011) Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914\u2013923","journal-title":"Lancet"},{"key":"7827_CR21","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2147\/OTT.S148496","volume":"11","author":"Y Qian","year":"2018","unstructured":"Qian Y, Tao J, Li X, Chen H, Lu Q, Yang J, Pan H, Wang C, Zhou W, Liu X (2018) Peripheral inflammation\/immune indicators of chemosensitivity and prognosis in breast cancer patients treated with neoadjuvant chemotherapy. OncoTargets Ther 11:1423\u20131432","journal-title":"OncoTargets Ther"},{"key":"7827_CR22","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"7827_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"7827_CR24","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s12282-023-01483-0","volume":"30","author":"H Morikawa","year":"2023","unstructured":"Morikawa H, Oba T, Kiyosawa N, Iji R, Amitani M, Chino T, Shimizu T, Ono M, Ito T, Kanai T, Maeno K, Ito KI (2023) Significance of skeletal muscle index-to-body mass index ratio as a predictor of post-surgical bleeding after mastectomy in patients with breast cancer. Breast Cancer 30:933\u2013942","journal-title":"Breast Cancer"},{"key":"7827_CR25","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/1078-0432.CCR-16-0940","volume":"23","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, Benbow JM, Muss HB (2017) Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 23:658\u2013665","journal-title":"Clin Cancer Res"},{"key":"7827_CR26","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/jcsm.13578","volume":"15","author":"HJ Meyer","year":"2024","unstructured":"Meyer HJ, Dermendzhiev T, Hetz M, Osterhoff G, Kleber C, Denecke T, Henkelmann J, Werdehausen R, Hempel G, Struck MF (2024) Body composition parameters in initial CT imaging of mechanically ventilated trauma patients: single-centre observational study. J Cachexia Sarcopenia Muscle 15:2437\u20132446","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7827_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12:298\u2013306","journal-title":"Nat Rev Cancer"},{"key":"7827_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.breast.2016.10.014","volume":"31","author":"HN Rier","year":"2017","unstructured":"Rier HN, Jager A, Sleijfer S, Van Rosmalen J, Kock MCJM, Levin M-D (2017) Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 31:9\u201315","journal-title":"Breast"},{"key":"7827_CR29","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1007\/s00330-023-09524-0","volume":"33","author":"A Surov","year":"2023","unstructured":"Surov A, Strobel A, Borggrefe J, Wienke A (2023) Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis. Eur Radiol 33:6426\u20136437","journal-title":"Eur Radiol"},{"key":"7827_CR30","doi-asserted-by":"publisher","first-page":"1309681","DOI":"10.3389\/fonc.2024.1309681","volume":"14","author":"ZH Li","year":"2024","unstructured":"Li ZH, Xu T, Zhang YJ, Jiang JH, Mi YZ, Li JX, Shen J, Fu YR, Qin BY, Lin F, Fu DJ, Yue MJ, Ma SM, Li QF (2024) Dynamic changes in body composition during XELOX\/SOX chemotherapy in patients with gastric cancer. Front Oncol 14:1309681","journal-title":"Front Oncol"},{"key":"7827_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.893333","volume":"13","author":"T Xu","year":"2022","unstructured":"Xu T, Li ZH, Liu T, Jiang CH, Zhang YJ, Li H, Jiang Y, Zhao J, Guo WJ, Guo JY, Wang L, Li JX, Shen J, Jin GW, Zhang ZW, Li QF (2022) Progress in research on antitumor drugs and dynamic changes in skeletal muscles. Front Pharmacol 13:893333","journal-title":"Front Pharmacol"},{"key":"7827_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10120-014-0381-z","volume":"18","author":"Y Kodera","year":"2015","unstructured":"Kodera Y (2015) More than 6 months of postoperative adjuvant chemotherapy results in loss of skeletal muscle: a challenge to the current standard of care. Gastric Cancer 18:203\u2013204","journal-title":"Gastric Cancer"},{"key":"7827_CR33","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/jhn.12811","volume":"34","author":"BS van der Meij","year":"2021","unstructured":"van der Meij BS, Teleni L, McCarthy AL, Isenring EA (2021) Cancer cachexia: an overview of diagnostic criteria and therapeutic approaches for the accredited practicing dietitian. J Hum Nutr Diet 34:243\u2013254","journal-title":"J Hum Nutr Diet"},{"key":"7827_CR34","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1016\/j.ejso.2020.04.044","volume":"46","author":"K Sugawara","year":"2020","unstructured":"Sugawara K, Yamashita H, Urabe M, Okumura Y, Yagi K, Aikou S, Seto Y (2020) Poor nutritional status and sarcopenia influences survival outcomes in gastric carcinoma patients undergoing radical surgery. Eur J Surg Oncol 46:1963\u20131970","journal-title":"Eur J Surg Oncol"},{"key":"7827_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.981533","volume":"9","author":"P Ding","year":"2022","unstructured":"Ding P, Lv J, Sun C, Chen S, Yang P, Tian Y, Zhou Q, Guo H, Liu Y, Zhao Q (2022) Combined systemic inflammatory immunity index and prognostic nutritional index scores as a screening marker for sarcopenia in patients with locally advanced gastric cancer. Front Nutr 9:981533","journal-title":"Front Nutr"},{"key":"7827_CR36","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1111\/cas.12488","volume":"105","author":"Y Funahashi","year":"2014","unstructured":"Funahashi Y, Okamoto K, Adachi Y, Semba T, Uesugi M, Ozawa Y, Tohyama O, Uehara T, Kimura T, Watanabe H, Asano M, Kawano S, Tizon X, McCracken PJ, Matsui J, Aoshima K, Nomoto K, Oda Y (2014) Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 105:1334\u20131342","journal-title":"Cancer Sci"},{"key":"7827_CR37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","volume":"110","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial\u2013mesenchymal transition (EMT) to mesenchymal\u2013epithelial transition (MET) states. Br J Cancer 110:1497\u20131505","journal-title":"Br J Cancer"},{"key":"7827_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10549-023-07111-x","volume":"203","author":"T Shimizu","year":"2024","unstructured":"Shimizu T, Oba T, Oshi M, Ito K-I (2024) Eribulin promotes proliferation of CD8+ T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells. Breast Cancer Res Treat 203:57\u201371","journal-title":"Breast Cancer Res Treat"},{"key":"7827_CR39","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/GME.0000000000000745","volume":"24","author":"HK Neilson","year":"2017","unstructured":"Neilson HK, Farris MS, Stone CR, Vaska MM, Brenner DR, Friedenreich CM (2017) Moderate-vigorous recreational physical activity and breast cancer risk, stratified by menopause status: a systematic review and meta-analysis. Menopause 24:322\u2013344","journal-title":"Menopause"},{"key":"7827_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10654-014-9916-1","volume":"29","author":"S Zhong","year":"2014","unstructured":"Zhong S, Jiang T, Ma T, Zhang X, Tang J, Chen W, Lv M, Zhao J (2014) Association between physical activity and mortality in breast cancer: a meta-analysis of cohort studies. Eur J Epidemiol 29:391\u2013404","journal-title":"Eur J Epidemiol"},{"key":"7827_CR41","doi-asserted-by":"publisher","first-page":"103665","DOI":"10.1016\/j.esmoop.2024.103665","volume":"9","author":"O Garrone","year":"2024","unstructured":"Garrone O, Paccagnella M, Abbona A, Ruatta F, Vanella P, Denaro N, Tomasello G, Croce N, Barbin F, Rossino MG, La Porta CAM, Sapino A, Torri V, Albini A, Merlano MC (2024) Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete response-the Neo-Runner study. ESMO Open 9:103665","journal-title":"ESMO Open"},{"key":"7827_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10549-024-07266-1","volume":"205","author":"TM Campbell","year":"2024","unstructured":"Campbell TM, Campbell EK, Culakova E, Blanchard LM, Wixom N, Guido JJ, Fetten J, Huston A, Shayne M, Janelsins MC, Mustian KM, Moore RG, Peppone LJ (2024) A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes. Breast Cancer Res Treat 205:257\u2013266","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07827-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07827-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07827-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:48:37Z","timestamp":1762174117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07827-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7827"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07827-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and approved by the ethics committee of Shinshu University (approval no. 4672).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Given the retrospective nature of the study using anonymized data, the requirement for written informed consent was waived. An opt-out option was provided via the institutional website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}